

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAY 30 2002

(use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/051,320
Filing Date	January 18, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	NB 2019.00

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number – Kind Code ² (if known)			
	1	US-3,852,266	12/03/74	Kiyanagi et al.	
	2	US-4,247,544	01/27/81	Bergstrom et al.	
	3	US-4,267,171	05/12/81	Bergstrom et al.	
	4	US-4,542,210	09/17/85	Sakata et al.	
	5	US-4,816,570	03/28/89	Farquhar	
	6	US-4,948,882	08/14/90	Ruth	
	7	US-4,975,278	12/04/90	Senter et al.	
	8	US-5,070,082	12/03/91	Murdock et al.	
	9	US-5,077,282	12/31/91	Murdock et al.	
	10	US-5,077,283	12/31/91	Murdock et al.	
	11	US-5,085,983	02/04/92	Scanlon	
	12	US-5,116,827	05/26/92	Murdock et al.	
	13	US-5,212,161	05/18/93	Moriniere et al.	
	14	US-5,212,291	05/18/93	Murdock et al.	
	15	US-5,233,031	08/03/93	Borch et al.	
	16	US-5,264,618	11/23/93	Felgner et al.	
	17	US-5,457,187	10/10/95	Gmeiner et al.	
	18	US-5,459,127	10/17/95	Felgner et al.	
	19	US-5,521,161	05/28/96	Malley et al.	
	20	US-5,616,564	04/01/97	Rapaport	
	21	US-5,627,165	05/06/97	Glazier	
	22	US-5,645,988	07/08/97	Vande Woude et al.	
	23	US-5,663,321	09/02/97	Gmeiner et al.	
	24	US-5,798,340	08/25/98	Bischofberger et al.	
	25	US-5,981,507	11/09/99	Josephson et al.	
	26	US-6,245,750 B1	06/12/01	Shepard	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)				
	27	GB 982,776	02/10/65	The Wellcome Foundation		
	28	WO 91/17424	11/14/91	Vical, Inc.		
	29	WO 93/06120 A1	04/01/93	University of Rochester		
	30	WO 94/03467	02/17/94	Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic		
	31	WO 94/22483	10/13/94	D-Pharm, Ltd.		

32	WO 95/08556	03/30/95	Amersham Int'l. PLC.	
33	WO 96/03151A2	02/08/96	Cancer Research Campaign Technology	
34	WO 96/07413A1	03/14/96	University of Georgia Research Foundation, Inc., et al.	
35	WO 96/10030	04/04/96	Isis Pharmaceuticals, Inc.	
36	WO 96/29336	09/26/96	Medical Research Council, et al.	
37	WO 96/40088	12/19/96	Hostettler	
38	WO 96/40708	12/19/96	La Jolla Pharmaceuticals Co.	
39	WO 97/28179	08/07/97	The Regents of the University of California	
40	WO 99/08110	02/18/99	NewBiotics, Inc.	
41	WO 99/20741	04/29/99	Geron Corporation	
42	WO 99/23104	05/14/99	The Government of the United States of America represented by The Secretary of Health and Human Services	
43	WO 99/37753	07/29/99	NewBiotics, Inc.	
44	WO 01/07454 A1	02/01/01	NewBiotics, Inc.	
45	WO 01/07088 A2	02/01/01	NewBiotics, Inc.	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

MAY 30 2002

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 11

Complete if Known

Application Number	10/051,320
Filing Date	January 18, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	NB 2019.00

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	1	ABRAHAM, T.W., et al. (1996) "Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-β-arabinofuranosylcytosine: Evidence of phosphoramidase activity" <i>J. Med. Chem.</i> 39:4569-4575.	
	2	AKDAS, A., et al. (1996) "Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder" <i>Eur. Urol.</i> 29:483-486.	
	3	ALMASAN, A., et al. (1995) "Genetic instability as a consequence of inappropriate entry into and progression through S-phase" <i>Cancer & Metastasis Rev.</i> 14:59-73.	
	4	ALMASAN, A., et al. (June 1995) "Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis" <i>PNAS, USA</i> 92:5436-5440.	
	5	ANDERSEN, T.I., et al. (1995) "Detection of c-erbB-2 related protein in sera from breast cancer patients" <i>Acta Oncol.</i> 34(4):499-504.	
	6	ANGLADA, J.M., et al. (July-August 1996) "N,N'-cyclization of carbodiimides with 2-(bromomethyl)acrylic acid. A direct entry to the system 5-methylene-6H-pyrimidine-2,4-dione, a new class of thymine analogues" <i>J. Heterocyclic Chem.</i> 33:1259-1270.	
	7	ANTELMAN, D., et al. (1995) "Inhibition of tumor cell proliferation <i>in vitro</i> and <i>in vivo</i> by exogenous p110 ^{RB} , the retinoblastoma tumor suppressor protein" <i>Oncogene</i> 10:697-704.	
	8	ASAKURA, J., et al. (1988) "Cerium(IV) catalyzed iodination at C5 of uracil nucleosides" <i>Tetrahedron Lett.</i> 29(23):2855-2858.	
	9	ASAKURA, J., et al. (1990) "Cerium(IV)-mediated halogenation at C-5 of uracil derivatives" <i>J. Org. Chem.</i> 55:4929-4933.	
	10	ASCHELE, C. et al. (June 1999) "Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy" <i>J. Clin. Oncol.</i> 17(6):1760-1770.	
	11	AYISI, N. K., et al. (1933) "Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5'-monophosphate with adenine arabinoside-5'-monophosphate" <i>Antiviral Res.</i> 3:161-174.	
	12	BALZARINI, J., et al. (1987) "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene" <i>Mol. Pharmacol.</i> 32:410-416.	
	13	BALZARINI, J., et al. (1993) "Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antitherapeutic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2" <i>J. Biol. Chem.</i> 268(9):6332-6337.	
	14	BALZARINI, J., et al. (1995) "Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line" <i>Meth. Find. Exptl. Clin. Pharmacol.</i> 7(1):19-28.	
	15	BALZARINI, J., et al. (1996) "Anti-HIV and anti-HIV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109" <i>Biochem. Biophys. Res. Commun.</i> 225:363-369.	
	16	BALZARINI, J., et al. (1997) "Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyporphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus" <i>FEBS Lett.</i> 410:324-328.	
	17	BALZARINI, J., et al. (July 1996) "Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives" <i>PNAS USA</i> 93:7295-7299.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
O I P E MAY 30 2002 P R O C E S S I N G P A T E N T & T R A D E M A R K O F F I C E	18	BANERJEE, D., et al. (1995) "Molecular mechanisms of resistance to antifolates, a review" <i>Acta Biochemical Polonica</i> 42(4):457-464.	
	19	BANERJEE, D., et al. (October 1998) "Role of E2F-1 in chemosensitivity" <i>Can. Res.</i> 58:4292-4296.	
	20	BARBATO, S., et al. (1989) "Synthesis of bridged pyrimidine nucleosides and triazo [4, 3-c] pyrimidine nucleoside analogues" <i>Nucleosides & Nucleotides</i> 8(4):515-528.	
	21	BARBOUR, K.W., et al. (1992) "A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells" <i>Mol. Pharmacol.</i> 42:242-248.	
	22	BARR, P.J., et al. (1981) "Inhibition of thymidylate synthetase by 5-alkynyl-2'-deoxyuridylates" <i>J. Med. Chem.</i> 24(12):1385-1388.	
	23	BARR, P.J., et al. (1983) "Reaction of 5-ethynyl-2'-deoxyuridylate with thiols and thymidylate synthetase" <i>Biochem.</i> 22:1696-1703.	
	24	BARR, P.J., et al. (1983) "Thymidylate synthetase-catalyzed conversions of <i>E</i> -5-(2-Bromovinyl)-2'-deoxyuridylate" <i>J. Biol. Chem.</i> 258(22):13627-13631.	
	25	BARRETT, J.E., et al. (1998) "Trapping of the C5 methylene intermediate in thymidylate synthase" <i>J. Am. Chem. Soc.</i> 120:449-450.	
	26	BELT, J.A., et al. (1993) "Nucleoside Transport in Normal and Neoplastic Cells" <i>Advan. Enzyme Regul.</i> 33:235-252.	
	27	BENZARIA, S., et al. (1996) "Synthesis, <i>in vitro</i> antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability" <i>J. Med. Chem.</i> 39:4958-4965.	
	28	BERGSTROM, D.E., et al. (1981) "C-5 substituted pyrimidine nucleosides. 3. Reaction of allylic chlorides, alcohol, and acetates with pyrimidine nucleoside derived organopalladium intermediates" <i>J. Org. Chem.</i> 46(7):1432-1441.	
	29	BERGSTROM, D.E., et al. (1984) "Synthesis of (<i>E</i>)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: potent and unusually selective antiviral activity of (<i>E</i>)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1" <i>J. Med. Chem.</i> 27:279-284.	
	30	BERTINO, J.R., et al. (1996) "Resistance mechanism to methotrexate in tumors" <i>Stem Cells</i> 14:5-9.	
	31	BERKOW, R., et al. (1992) "The Merck Manual of Diagnosis and Therapy" 16 th Edition, Merck & Co., Rahway, New Jersey, p. 1278.	
	32	BIBLE, K.C. et al. (August 15, 1997) "Cytotoxic Surgery between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration" <i>Cancer Res.</i> 57:3375-3380.	
	33	BIGGE, C.F., et al. (1980) "Palladium-catalyzed coupling reactions of uracil nucleosides and nucleosides" <i>J. Am. Chem. Soc.</i> 102(6):2033-2038.	
	34	BOSSLET, K., et al. (1995) "A novel one-step tumor-selective prodrug activation system" <i>Tumor Targeting</i> 1:45-50.	
	35	BOSSLET, K., et al. (March 15, 1998) "Elucidation of the mechanism enabling tumor selective prodrug monotherapy" <i>Cancer Res.</i> 58:1195-1201.	
	36	BRISON, O. (1993) "Gene amplification and tumor progression" <i>Biochem. Biophys. Acta</i> 1155:25-41.	
	37	BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 th Edition Doxifluridine, page 3493.	
	38	BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 th Edition Floxuridine, page 4148.	
	39	BUDAVARI, S. (July 1996) (Ed.), "The Merck Index" 12 th Edition Idoxuridine, page 4934.	
	40	CARL, P.L., et al. (1980) "Protease-activated 'prodrugs' for cancer chemotherapy" <i>PNAS USA</i> 77(4):2224-2228.	
	41	CARRERAS, C.W., et al. (1995) "The catalytic mechanism and structure of thymidylate synthase" <i>Annu. Rev. Biochem.</i> 64:721-762.	
	42	CARTER, P., et al. (May 1992) "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy" <i>PNAS USA</i> 89:4285-4289.	
	43	CAVA, M.P., et al. (1985) "Thionation reactions of lawesson's reagents" <i>Tetrahedron</i> 41(22):5061-5087.	
	44	CHAKRAVARTY, P.K., et al. (1983) "Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin" <i>J. Med. Chem.</i> 26(5):638-644.	
	45	CHAUDHURI, N.C., et al. (1995) "Very high affinity DNA recognition by bicyclic and cross-linked oligonucleotides" <i>J. Am. Chem. Soc.</i> 117:10434-10442.	
	46	CHEN, L., et al. (March 15, 1996) "Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene" <i>Can. Res.</i> 56:1331-1340.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
Q I P E MAY 30 2002 USPTO - TRADE OFFICE SEARCHED	47	CHO, Y.M., et al. (1994) "(E)-5-(3-oxopropen-1-yl)-2'-deoxyuridine and (E)-5-(3-oxopropen-1-yl)-2',3'-dideoxyuridine; new antiviral agents: Syntheses and biological activity" <i>Tetrahedron Lett.</i> 35(8):1149-1152.	
	48	CHOU, T.C., et al. (1984) "Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors" <i>Adv. Enzyme Regul.</i> 22:27-55.	
	49	CLARKE, R., et al. (1996) "Animal models of breast cancer. Their diversity and role in biomedical research" <i>Breast Can. Res. & Treatment</i> 39:1-6.	
	50	COLACINO, J.M. (1996) "Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fluridine (FIAU)" <i>Antiviral Res.</i> 29:125-139.	
	51	COLLINS, J.M., et al. (August 1999) "Suicide Prodrugs Activated by Thymidylate Synthase: Rationale for Treatment and Noninvasive Imaging of Tumors with Deoxyuridine Analogues" <i>Clin. Cancer Res.</i> 5:1976-1981.	
	52	CONNORS, T.A. (1986) "Prodrugs in cancer chemotherapy" <i>Xenobiotica</i> 16(10/11):975-988.	
	53	CONNORS, T.A. (1996) "Is there a future for cancer chemotherapy" <i>Annals Oncol.</i> 7:445-452.	
	54	CONNORS, T.A., et al. (1995) "Prodrugs in cancer chemotherapy" <i>Stem Cells</i> 13:501-511.	
	55	COPUR, S., et al. (1995) "Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil" <i>Biochem. Pharmacol.</i> 49(10):1419-1426.	
	56	CRISP, G.T. (1989) "Synthesis of 5-alkenyl-2'-deoxyuridines via organostannanes" <i>Synthetic Commun.</i> 19(11&12):2117-2123.	
	57	CRUICKSHANK, K.A., et al. (1988) "Oligonucleotide labeling: A concise synthesis of a modified thymidine phosphoramidite" <i>Tetrahedron Lett.</i> 29(41):5221-5224.	
	58	CURTIN, N.J., et al. (May 1, 1991) "Mechanism of Cell Death following Thymidylate Synthase Inhibition: 2'-Deoxyuridine-5'-triphosphate Accumulation, DNA Damage, and Growth Inhibition following Exposure to CB3717 and Dipyridamole" <i>Cancer Res.</i> 51:2346-2352.	
	59	DAGLE, J.M., et al. (August 25, 1990) "Targeted Degradation of mRNA in <i>Xenopus</i> oocytes and Embryos Directed by Modified Oligonucleotides: Studies of An2 and Cyclin in Embryogenesis" <i>Nucleic Acids Research</i> 18(16):4751-4757.	
	60	DALE, R.M.K., et al. (August 1973) "The synthesis and enzymatic polymerization of nucleotides containing mercury: Potential tools for nucleic acid sequencing and structural analysis" <i>PNAS USA</i> 70(8):2238-2242.	
	61	DAVISSON, V.J., et al. (1989) "Expression of human thymidylate synthase in <i>Escherichia coli</i> " <i>J. Biol. Chem.</i> 264(16):9145-9148.	
	62	DAVISSON, V.J., et al. (1994) "Expression of human thymidylate synthase in <i>Escherichia coli</i> . (Additions and corrections)" <i>J. Biol. Chem.</i> 269(48):30740.	
	63	DE CLERCQ, E. (1994) "Antiviral Activity Spectrum and Target of Action of Different Classes of Nucleoside Analogues" <i>Nucleosides & Nucleotides</i> 13(6&7):1271-1295.	
	64	DE CLERCQ, E., et al. (1983) "Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides" <i>J. Med. Chem.</i> 26:661-666.	
	65	DE CLERCQ, E., et al. (September 18, 1978) "Antiviral Activity of Novel Deoxyuridine Derivatives" <i>Current Chemotherapy: Proceedings of the International Congress of Chemotherapy</i> 1:352-354.	
	66	DE CLERCQ, E., et al. (October 1997) "In Search of a Selective Antiviral Chemotherapy" <i>Clin. Microbiol. Rev.</i> 10(4):674-693.	
	67	DICKER, A.P., et al. (December 1993) "Methotrexate resistance in an <i>in vivo</i> mouse tumor due to a non-active-site dihydrofolate reductase mutation" <i>PNAS USA</i> 90:11797-11801.	
	68	DIRVEN, H.A.A.M., et al. (April 15, 1995) "The role of human glutathione S-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa" <i>Can. Res.</i> 55:1701-1706.	
	69	DORR, R.T., et al. (1994) "PALA" In: <i>Cancer Chemotherapy Handbook</i> : Appleton & Lange, Norwalk, Connecticut: 768-773.	
	70	DRAKE, J.C., et al. (1996) "Resistance to Tomudex (ZD1694): Multifactorial in Human Breast and Colon Carcinoma Cell Lines" <i>Biochem. Pharmacol.</i> 51:1349-1355.	
	71	DUNN III, W.J., et al. (1996) "Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis" <i>J. Med. Chem.</i> 39:4825-4832.	
	72	DYER, R.L., et al., "The synthesis of E-5-(2-bromovinyl)-2'-deoxyuridine from 2'-deoxy-5-iodouridine" in: <i>Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods and Techniques</i> , Townsend et al. (Eds.), John Wiley & Sons, Inc., New York, pp. 79-83.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	73	ECCLES, S.A., et al. (1994-1995) "Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy" <i>Invasion Metastasis</i> 14:337-348.	
	74	EDLER, D., et al. (February 2000) "Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival" <i>Clinical Cancer Research</i> 6:488-492.	
	75	EISENBRAND, G., et al. (1996) "An approach towards more selective anticancer agents" <i>J. Synthetic Organic Chem.</i> 10:1246-1258.	
	76	EVARD, A., et al. (1996) "An in vitro nucleoside analog screening method for cancer gene therapy" <i>Chem. Abstracts</i> 126:Abstract No. 26514, Issue No. 3, p.32, January 20, 1997.	
O I P E MAY 30 2002 PATENT & TRADEMARK OFFICE	77	EVARD, A., et al. (1996) "An in vitro nucleoside analog screening method for cancer gene therapy" <i>Cell Biol. Toxicol.</i> 12:345-350.	
	78	FAN, J., et al. (1997) "Functional roles of E2F in cell cycle regulation" <i>Oncogene</i> 14:1191-1200.	
	79	FARQUHAR, D., et al. (1994) "Synthesis and antitumor evaluation of bis(pivaloyloxy)methyl 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): A strategy to introduce nucleotides into cells" <i>J. Med. Chem.</i> 37:3902-3909.	
	80	FARQUHAR, D., et al. (1995) "5'-[4-(pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: A membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP)" <i>J. Med. Chem.</i> 38:488-495.	
	81	FELIP, E., et al. (1995) "Overexpression of c-erbB-2 in epithelia ovarian cancer" <i>Cancer</i> 75(8):2147-2152.	
	82	FINCH, S.C., et al. (1991) "Radiation Injury" In: Harrison's Principles of Internal Medicine, 12 th edition: McGraw-Hill, Inc., New York, NY:2004-2208.	
	83	FINER-MOORE, J., et al. (1993) "Refined structures of substrate-bound and phosphate-bound thymidylate synthase from <i>Lactobacillus casei</i> " <i>J. Mol. Biol.</i> 232:1101-1116.	
	84	FINER-MOORE, J.S., et al. (1994) "Crystal structure of thymidylate synthase from T4 phage: Component of a deoxynucleoside triphosphate-synthesizing complex" <i>Biochem.</i> 33:15459-15468.	
	85	FIRESTONE, W.M., et al. (May 1990) "A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma" <i>J. Investigative Dermatol.</i> 94:657-661.	
	86	FIRESTONE, W.M., et al. (July 2, 1990) "A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma" <i>Chem. Abstracts</i> 113:Abstract No. 254.	
	87	FREED, J.J., et al. (1989) "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells" <i>Biochem. Pharmacol.</i> 38(19):3193-3198.	
	88	FREEMANTLE, S.J., et al. (1995) "Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694" <i>British Journal of Cancer</i> 71:925-930.	
	89	FRIES, K.M., et al., (1995) "Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs" <i>J. Med. Chem.</i> 38(14):2672-2680.	
	90	FUNK, J.O. (1999) "Cancer cell cycle control" <i>Anticancer Research</i> 19:4772-4780.	
	91	GARRETT, C.G., et al. (1979) "Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo-and 5-iodo-2'-deoxyuridylate" <i>Biochem.</i> 18(13):2798-2804.	
	92	GOEL, R., et al. (February 1989) "Selective Intraperitoneal Biochemical Modulation of Methotrexate by Dipyridamole" <i>J. Clin. Oncol.</i> 7(2):262-269.	
	93	GOLDBERG, J.L., et al. (1997) "Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos" <i>Am. J. Respir. Cell Mol. Biol.</i> 17:265-271.	
	94	GOLDSTEIN, J.L., et al. (1991) "Genetic aspects of disease" In: Harrison's Principles of Internal Medicine, 12 th edition: McGraw-Hill, Inc., New York, NY:21-76.	
	95	GOODWIN, J.T., et al. (1993) "Incorporation of alkylthiol chains at C-5 of deoxyuridine" <i>Tetrahedron Lett.</i> 34(35):5549-5552.	
	96	GORLICK, R., et al. (December 1999) "Drug Resistance in Colon Cancer" <i>Semin. Oncol.</i> 26(6):606-611.	
	97	GOTTESMAN, M.M., et al., (1995) "Genetic analysis of the multidrug transporter" <i>Annu. Rev. Genet.</i> 29:607-649.	
	98	GRAHAM, D., et al. (1998) "DNA duplexes stabilized by modified monomer residues: synthesis and stability" <i>J. Chem. Soc. Perkin Trans. 1</i> :1131-1138.	
	99	GREM, J. L., et al. (April 1992) "Biochemical Modulation of Fluorouracil by Dipyridamole: Preclinical and Clinical Experience" <i>Semin Oncol.</i> 19(2)(3):56-65.	
	100	GRIFFITH, D. A., et al. (1990) "Differential Inhibition of Nucleoside Transport Systems in Mammalian Cells by a New Series of Compounds Related to Lidoflazine and Mioflazine" <i>Biochem. Pharmacol.</i> 40(10):2297-2303.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	101	GROS, P., et al. (1986) "Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells" <i>PNAS USA</i> 83:337-341.	
	102	GROS, P., et al. (1986) "Isolation and expression of a complementary DNA that confers multidrug resistance" <i>Nature</i> 323:728-7731.	
	103	GROS, P., et al. (1986) "Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins" <i>Cell</i> 47:371-380.	
	104	GUDKOV, A.V., et al. (1987) "Cloning and characterization of DNA sequences amplified in multidrug-resistant djungarian hamster and mouse cells" <i>Somat. Cell. Mol. Genet.</i> 13(6):609-619.	
<i>CIPE</i> MAY 30 2002 PATENT & TRADEMARK OFFICE			
	105	HAKIMELAHI, G.H., et al. (November 10, 1995) "Design, Synthesis and Structure-Activity Relationship of Novel Dinucleotide Analogs" <i>38</i> (23):4648-4659.	
	106	HARDY, L.W., et al. (1987) "Atomic structure of thymidylate synthase: Target for rational drug design" <i>Science</i> 235:448-455.	
	107	HARRIS, M.P., et al. (1996) "Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein" <i>Cancer Gene Ther.</i> 3(2):121-130.	
	108	HASHIMOTO, Y., et al. (1987) "Simple separation of tritiated water and [³ H] deoxyuridine from [5- ³ H] deoxyuridine 5'-monophosphate in the thymidylate synthase assay" <i>Anal. Biochem.</i> 167:340-346.	
	109	HENGSTSCHLÄGER, M., et al. (1996) "The role of p16 in the E2F-dependent thymidine kinase regulation" <i>Oncogene</i> 12:1635-1643.	
	110	HOBBS, F.W. (1989) "Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids" <i>J. Org. Chem.</i> 54:3420-3422.	
	111	HOLÝ, A., et al. (1999) "Structure-Antiviral Activity Relationship in the Series of Pyrimidine and Purine N-[2-(2-Phosphonomethoxy)ethyl] Nucleotide Analogues. 1. Derivatives Substituted at the Carbon Atoms of the Base" <i>J. Med. Chem.</i> 42:2064-2086.	
	112	HORIKOSHI, T., et al. (1992) "Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction" <i>Can. Res.</i> 52:108-116.	
	113	HORN, D.M., et al. (1997) "Fialuridine is phosphorylated and inhibits DNA synthesis isolated rat hepatic mitochondria" <i>Antiviral Res.</i> 34:71-74.	
	114	HOSTETLER, K.Y., et al. (1997) "Enhanced oral absorption and antiviral activity of 1-o-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, <i>in vitro</i> " <i>Biochem. Pharmacol.</i> 53:1815-1822.	
	115	HOUZE, T.A., et al., (1997) "Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction" <i>Tumor Biol.</i> 18:53-68.	
	116	HOWELL, S. B., et al. (June 15, 1989) "Comparison of the Synergistic Potentiation of Etoposide, Doxorubicin, and Vinblastine Cytotoxicity by Dipyridamole" <i>Cancer Res.</i> 49:3178-3183.	
	117	HSIAO, L.Y., et al. (1981) "Synthesis of 5'-thymidinyl bis(1-aziridinyl) phosphinates as antineoplastic agents" <i>J. Med. Chem.</i> 24:887-889.	
	118	HUANG, W., et al. (1997) "Active site general catalysts are not necessary for some proton transfer reactions of thymidylate synthase" <i>Biochem.</i> 36:1869-1873.	
	119	HUDZIAK, R.M., et al. (1990) "Selection for transformation and <i>met</i> protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor α " <i>Cell Growth & Differentiation</i> 1:129-134.	
	120	HUDZIAK, R.M., et al. (July 1988) "Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells" <i>PNAS USA</i> 85:5102-5106.	
	121	HUSAIN, I., et al. (January 15, 1994) "Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy" <i>Cancer Research</i> 54:539-546.	
	122	HUSAK, R., et al. (1998) "Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient" <i>British J. Dermatol.</i> 139:118-121.	
	123	IMAI, K., et al. (1969) "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides" <i>J. Org. Chem.</i> 34(6):1547-1550.	
	124	JACKMAN, A.L., et al. (1995) "Folate-based thymidylate synthase inhibitors as anticancer drugs" <i>Annals of Oncology</i> 6:871-881.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
--------------------	-----------------------	---	----------------

	125	JACKMAN, A.L., et al. (1995) "Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation" <i>Anti-Cancer Drug Design</i> 10:573-589.	
	126	JOHNSTON, P.G. (1994) "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer" <i>J. Clin. Oncol.</i> 12(12):2640-2647.	
	127	JOHNSTON, P.G., et al. (1991) "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue" <i>Can. Res.</i> 51:6668-6676.	
	128	JONES, R.G., et al. (August 20, 1953) "New methods of synthesis of β -aminoethylpyrazoles" <i>J. Am. Cancer Res.</i> 75:4048-4052.	
<i>IPF</i> MAY 30 2002 RADENMAKER OFFICE		129 KAMB, A., et al. (1998) "Cyclin-dependent kinase inhibitors and human cancer" <i>Curr. Top. Microbiol. Immunol.</i> 227:139-148.	
	130	KASHANI-SABET, M., et al. (October 15, 1988) "Detection of drug resistance in human tumors by <i>in vitro</i> enzyme amplification" <i>Can. Res.</i> 48:5775-5778.	
	131	KATKI, A.G., et al. (March 1998) "Prodrugs Activated by Thymidylate Synthase: Treatment of Tumors with Deoxyuridine Analogs" <i>Proc. Amer. Assoc. Cancer Res.</i> 39, Abstract No. 1275.	
	132	KLECKER, R.W., et al. (1994) "Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'Deoxy- β -D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells" <i>Mol. Pharmacol.</i> 46:1204-1209.	
	133	KNIGHTON, D.R., et al. (1994) "Structure and kinetic channeling in bifunctional dihydrofolate reductase-thymidylate synthase" <i>Nature Struct. Biol.</i> 1(3):186-194.	
	134	KOBAYASHI, H., et al. (November 1995) "Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors" <i>Jpn. J. Can. Res.</i> 86:1014-1018.	
	135	KODAMA, E., et al. (1996) "Evaluation of antitherapeutic compounds using a gastric cancer cell line: Pronounced activity of BVDU against herpes simplex virus replication" <i>Microbiol. Immunol.</i> 40(5):359-363.	
	136	KRAJEWSKA, E., et al. (1982) "Pyrimidine ribonucleoside phosphorylase activity VS 5- and/or 6-substituted uracil and uridine analogues, including conformational aspects" <i>Biochem. Pharmacol.</i> 31(6):1097-1102.	
	137	KRAUPP, M., et al. (1995) "Membrane Transport of Nucleobases: Interaction with Inhibitors" <i>Gen. Pharmacol.</i> 26(6):1185-1190.	
	138	KUMAR, A., et al. (1990) "Synthesis and Biological Evaluation of Some Cyclic Phosphoramidate Nucleoside Derivatives" <i>J. Med. Chem.</i> 33(9):2368-2735.	
	139	KUNDU, N.G. (1993) "Synthesis and biological activities of [E]-5-(2-acetylvinyl) uracils" <i>Eur. J. Med. Chem.</i> 28:473-479.	
	140	KUROBOSHI, M., et al. (1991) "A facile synthesis of difluoromethylene compounds by oxidative fluorodesulfurization of dithioacetals using tetrabutylammonium dihydrogenfluoride and N-halo compounds" <i>SYNLETT</i> :909-910.	
	141	KUROBOSHI, M., et al. (1994) "A facile synthesis of α , α -difluoroalkyl ethers and carbonyl fluoride acetals by oxidative desulfurization-fluorination" <i>SYNLETT</i> :251-252.	
	142	LACKEY, D. B., et al. (2001) "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase" <i>Biochem. Pharmacol.</i> 61:179-189.	
	143	LAM, K.S. (1997) "Application of combinatorial library methods in cancer research and drug discovery" <i>Anticancer Drug Design</i> 12:145-167.	
	144	LARSSON, P.A., et al. (1996) "Thymidylate Synthase in Advanced Gastrointestinal and Breast Cancers" <i>Acta Oncological</i> 35(4):469-472.	
	145	LASIC, D.D. (April 11, 1996) "Doxorubicin in sterically stabilized liposomes" <i>Nature</i> 380:561-562.	
	146	LEE, Y.L., et al. (1997) "Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein" <i>Exp. Cell Res.</i> 234:270-276.	
	147	LEHMAN, N. L., et al. (2000) "Modulation of RTX cytotoxicity by thymidine and dipyridamole <i>in vitro</i> : implications for chemotherapy" <i>Cancer Chemother. Pharmacol.</i> 45:142-148.	
	148	LEICHMAN, C. G., et al. (October 1997) "Quantitation of Intratumoral Thymidylate Synthase Expression Predicts for Disseminated Colorectal Cancer Response and Resistance to Protracted-Infusion Fluorouracil and Weekly Leucovorin" <i>J. Clin. Oncol.</i> 15(10):3223-3229.	
	149	LENZ, H.J., et al. (May 1998) "p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site" <i>Clinical Cancer Research</i> 4:1227-1234.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
O P E MAY 30 2001 USPTO PATENT & TRADEMARK OFFICE	150	LES, A., et al. (1998) "Modeling of reaction steps relevant to deoxyuridylate (dUMP) enzymatic methylation and thymidylate synthase mechanism-based inhibition" <i>Journal of Biomolecular Structure & Dynamics</i> 15(4):703-715.	
	151	LEWIS, J.G., et al. (April 1996) "A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA" <i>PNAS USA</i> 93:3176-3181.	
	152	LI, W., et al. (1995) "Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines" <i>PNAS USA</i> 92:10436-10440.	
	153	LIN, W.Y., et al. (1997) "Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases" <i>Eur. J. Nucl. Med.</i> 24(6):590-595.	
	154	LIVAK, K.J., et al. (1992) "Detection of single base differences using biotinylated nucleotides with very long linker arms" <i>Nucl. Acids Res.</i> 20(18):4831-4837.	
	155	LIVINGSTONE, L.R., et al. (1992) "Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53" <i>Cell</i> 70:923-935.	
	156	LÖNN, U., et al. (1996) "Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy" <i>Cancer</i> 77(1):107-112.	
	157	LOOK, K.Y., et al. (1997) "Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma" <i>Anticancer Res.</i> 17:2353-2356.	
	158	LOVEJOY, E.A., et al. (1997) "Animal models and the molecular pathology of cancer" <i>J. Pathol.</i> 181:130-135.	
	159	MADEC, A., et al. (1998) "Some characteristics of fetal and adult isoenzymes of thymidine kinase in human breast cancers" <i>Bull. Cancer</i> 75:187-194.	
	160	MADER, R.M., et al. (1998) "Resistance to 5-fluorouracil" <i>Gen. Pharma.</i> 31(5):661-666.	
	161	MAHONY, C., et al. (March 1982) "Dipyridamole Kinetics" <i>Clin. Pharmacol. Ther.</i> 31(3):330-338.	
	162	MASTERS, J.N., et al. (1983) "The nucleotide sequence of the c DNA coding for the human dihydrofolic acid reductase" <i>Gene</i> 21:59-63.	
	163	MCGUIGAN, C. (1992) "Aryl phosphate derivative of AZT retain activity HIV1 in cell lines which are resistant to the action of AZT" <i>Antiviral Res.</i> 17:311-321.	
	164	MCGUIGAN, C. (1993) "Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT" <i>J. Med. Chem.</i> 36:1048-1052.	
	165	MCGUIGAN, C. (1996) "Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite" <i>J. Med. Chem.</i> 39:1748-1753.	
	166	MCGUIGAN, C. (1998) "Synthesis and evaluation of some masked phosphate esters of the anti-herpetic drug 882C (netivudine) as potential antiviral agents" <i>Antiviral Chem. Chemother.</i> 9:187-197.	
	167	MCGUIGAN, C., et al. (1994) "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase" <i>FEBS Lett.</i> 351:11-14.	
	168	MCINTEE, E.J., et al. (1997) "Probing the mechanism of action and decomposition of amino acid phosphomonooester amides of antiviral nucleoside prodrugs" <i>J. Med. Chem.</i> 40:3323-3331.	
	169	MCKAY, G.A., et al. (1994) "Broad spectrum aminoglycoside phosphotransferase type III from <i>Enterococcus</i> : Overexpression, purification, and substrate specificity" <i>Biochem</i> 33:6936-6944.	
	170	MEDEN, H., et al. (1994) "Elevated serum Levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy" <i>J. Cancer Res. Clin. Oncol.</i> 120:378-381.	
	171	MEIER, C., et al. (1997) "ADA-bypass by lipophilic cyclosal-ddAMP pro-nucleotides a second example of the efficiency of the cyclosal-concept" <i>Bioorg. & Med. Chem. Lett.</i> 7(12):1577-1582.	
	172	MEIER, C., et al. (1997) "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) – a new pro-nucleotide approach" <i>Bioorg. & Med. Chem. Lett.</i> 7(2):99-104.	
	173	MEIER, C., et al. (1997) "Cyclosal-pro-nucleotides: the design and biological evaluation of a new class of lipophilic nucleotide prodrugs" <i>International Antiviral News</i> 5(10):183-185.	
	174	MELTON, R.G., et al. (February 21, 1996) "Antibody-enzyme conjugates for cancer therapy" <i>J. Natl. Canc. Institute</i> 88(3/4):153-165.	
	175	MOBASHERY, S., et al (June 15, 1986) "Reactions of <i>Escherichia coli</i> TEM β -lactamase with cephalothin and with C ₁₀ -dipeptidyl cephalosporin esters" <i>J. Biol. Chem.</i> 261(17):7879-7887.	
	176	MOBASHERY, S., et al. (1986) "Conscripting β -lactamase for use in drug delivery. Synthesis and biological activity of a cephalosporin C ₁₀ -ester of an antibiotic dipeptide" <i>J. Am. Chem. Soc.</i> 108:1686-1688.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	177	MONTFORT, W.R., et al. (1997) "Thymidylate synthase: Structure, inhibition, and strained conformations during catalysis" <i>Pharmacol. Ther.</i> 76(1-3):29-43.	
	178	MONTGOMERY, J.A., et al. (1979) "Phosphonate analogue of 2'-deoxy-5-fluorouridylic acid" <i>J. Med. Chem.</i> 22(1):109-111.	
	179	MORGAN, A.S., et al. (June 15, 1998) "Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase" <i>Cancer Res.</i> 58:2568-2575.	
O I P E MAY 30 2002 TRADEMARK OFFICE	180	MURAKAMI, Y., et al. (1998) "Accumulation of genetic alterations and their significance in each primary human cancer and cell line" <i>Mutat. Res.</i> 400(1-2):421-437.	
	181	NAESENS, L., et al. (April 1997) "Anti-HIV Activity and Metabolism of Phosphoramidate Derivatives of D4T-MP with Variations in the Amino Acid Moiety" <i>Poster Session 1, The Tenth International Conference on Antiviral Research</i> , Hotel Nikko, Atlanta, GA, April 6-11, 1997; published in <i>Antiviral Research</i> 34(2):A54 (Abstract 40).	
	182	NAKANO, T., et al. (1994) "Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis" <i>Biochem.</i> 33:9945-9952.	
	183	NEGISHI, K., et al. (1996) "Enhancement of N4-aminocytidine-induced mutagenesis by Ni++ ion" <i>Nucl. Acids Symposium</i> 35:137-138.	
	184	NELSON, J. A., et al. (June 1984) "Potentiation of Methotrexate Toxicity by Dipyridamole" <i>Cancer Res.</i> 44:2493-2496.	
	185	NOOTER, K., et al. (1996) "Molecular mechanisms of multidrug resistance in cancer chemotherapy" <i>Pathol. Res. Pract.</i> 192:768-780.	
	186	OSAKI, M., et al. (1997) "5-fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: Role of the p53 gene" <i>Apoptosis</i> 2:221-226.	
	187	OSHIRO, Y., et al. (1992) "Genotoxic properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)" <i>Fund. Appl. Toxicol.</i> 18:491-498.	
	188	PARADISO, A., et al. (2000) "Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients" <i>British J. of Cancer</i> 82(3):560-567.	
	189	PARDO, E.G., et al. (1987) "The incorporation of deoxyuridine monophosphate into DNA increases the sister-chromatid exchange yield" <i>Exp. Cell Res.</i> 168:507-517.	
	190	PARK, N.-H., et al. (June 1982) "Chemotherapeutic efficacy of E-5-(2bromovinyl)-2'-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice" <i>J. Infectious Diseases</i> 145(6):909-913.	
	191	PEDERSEN-LANE, J., et al. (1997) "High-level expression of human thymidylate synthase" <i>Protein Expression and Purification</i> 10:256-262.	
	192	PEGRAM, M.D., et al. (1997) "The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells" <i>Oncogene</i> 15:537-547.	
	193	PERRY, K.M., et al. (1990) "Plastic adaptation toward mutations in proteins: Structural comparison of thymidylate synthases" <i>Proteins</i> 8:315-333.	
	194	PESTALOZZI, B.C., et al. (1997) "Prognostic importance of thymidylate synthase expression in early breast cancer" <i>J. Clin. Oncol.</i> 15(5):1923-1931.	
	195	PETERS, G.J., et al. (1995) "Thymidylate synthase and drug resistance" <i>Eur. J. Cancer</i> 31A(7/8):1299-1305.	
	196	PHELPS, M.E., et al. (1980) "Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates" <i>J. Med. Chem.</i> 23:1229-1232.	
	197	PLUTA, J., et al. (1999) "Synthesis and biological properties of 4-hydroxy, 4-thio-5-pyrimidine derivatives" <i>Boll. Chim. Farm.</i> 138(1):30-33.	
	198	PUPA, S.M., et al. (1993) "The extracellular domain of the c-erbB-2 oncprotein is released from tumor cells by proteolytic cleavage" <i>Oncogene</i> 8:2917-2923.	
	199	RAMU, N., et al. (1989) "Circumvention of Adriamycin Resistance by Dipyridamole Analogues: A structure-activity relationship Study" <i>Int. J. Cancer</i> 43:487-491.	
	200	ROBERTS, D.W. (1966) "An isotopic assay for thymidylate synthetase" <i>Biochem.</i> 5(11):3546-3548.	
	201	ROBINS, M.J., et al. (1981) "Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides" <i>Tetrahedron Lett.</i> 22:421-424.	
	202	ROBINS, M.J., et al. (1982) "Nucleic acid related compounds. 38. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and p-tolyl-protected nucleosides" <i>Can. J. Chem.</i> 60:554-557.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	203	ROBINS, M.J., et al. (1983) "Nucleic acid related compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derivated 5-substituted uracil bases and nucleosides" <i>J. Org. Chem.</i> 48 :1854-1862.	
	204	ROGULSKI, K.R., et al. (January 1, 1997) "Glioma cells transduced with an <i>Escherichia coli</i> CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity" <i>Hum. Gene Ther.</i> 8 :73-85.	
	205	ROMAIN, S., et al. (1995) "Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer" <i>Int. J. Cancer</i> 61 :7-12.	
	206	RONINSON, I.B., et al. (1984) "Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells" <i>Nature</i> 309 :626-628.	
<i>P E</i> MAY 30 2002 JC58 PATENTS & TRADEMARKS OFFICE	207	ROONEY, P. H., et al. (November 15, 1998) "Comparative Genomic Hybridization Analysis of Chromosomal Alterations Induced by the Development of Resistance to Thymidylate Synthase Inhibitors" <i>Cancer Res.</i> 58 :5042-5045.	
	208	ROTH, J.A., et al. (1999) "p53 tumor suppressor gene therapy for cancer" <i>Oncology</i> 13 (10)(5):148-154.	
	209	RUTH, J.L., et al. (1978) "C-5 substituted pyrimidine nucleosides. 1. Synthesis of C-5 allyl, propyl, and propenyl uracil and cytosine nucleosides via organopalladium intermediates" <i>J. Org. Chem.</i> 43 (14):2870-2876.	
	210	SABOULARD, D., et al. (1999) "Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine" <i>Mol. Pharmacol.</i> 56 :693-704.	
	211	SANTI, D.V. (February 1980) "Perspectives on the design and biochemical pharmacology of inhibitors of thymidylate synthetase" <i>J. Med. Chem.</i> 23 (2):103-111.	
	212	SASTRY, J.K., et al. (1992) "Membrane-permeable dideoxuryidine 5'-monophosphate analogue inhibits human immunodeficiency virus infection" <i>Mol. Pharmacol.</i> 41 :441-445.	
	213	SAUTER, G., et al. (1993) "Heterogeneity of erbB-2 gene amplification in bladder cancer" <i>Cancer Res.</i> 53 :2199-2203.	
	214	SCHIFFER, C.A., et al. (1995) "Crystal structure of human thymidylate synthase: A structural mechanism for guiding substrates into the active site" <i>Biochem.</i> 34 :16279-16287.	
	215	SCHIMKE, R.T. (1988) "Gene amplification in cultured cells" <i>J. Biol. Chem.</i> 263 (13):5989-5992.	
	216	SCHMOLL, H.-J. (1994) "Colorectal carcinoma: Current problems and future perspectives" <i>Ann. Oncol.</i> 5 (3):115-121.	
	217	SEGOVIA, M. (1994) "Leishmania gene amplification: A mechanism of drug resistance" <i>Annals Tropical Med. Parasitol.</i> 88 (2):123-130.	
	218	SHEPARD, H.M., et al. (1988) "Resistance of tumor cells to tumor necrosis factor" <i>J. Clin. Immunol.</i> 8 (5):333-341.	
	219	SIMON, S.M., et al. (April 1994) "Cell biological mechanisms of multidrug resistance in tumors" <i>PNAS USA</i> 91 :3497-3504.	
	220	SINGH, J., et al. (1993) "Studies on the preparation and isomeric composition of ¹⁸⁶ Re-pentavalent rhenium dimercaptosuccine acid complex" <i>Nucl. Med. Commun.</i> 14 :197-203.	
	221	SLAMON, D.J., et al. (1987) "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene" <i>Science</i> 235 :177-182.	
	222	SLAMON, D.J., et al. (1989) "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer" <i>Science</i> 244 :707-712.	
	223	SMITH, K.A., et al. (1995) "Regulation and mechanisms of gene amplification" <i>Phil. Trans. R. Soc. Lond.</i> 347 :49-56.	
	224	SNYDMAN, D.R., et al. (1996) "Analysis of trends in antimicrobial resistance patterns among clinical isolates of <i>Bacteroides fragilis</i> group species from 1990 to 1994" <i>Clinical Infectious Diseases</i> 23 (Suppl. 1):S54-S65.	
	225	STASCHKE, K.A., et al. (1994) "The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl-4-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell" <i>Antiviral Res.</i> 23 :45-61.	
	226	STOUT, T.J., et al. (1999) "Structure-based design of inhibitors specific for bacterial thymidylate synthase" <i>Biochem.</i> 38 :1607-1617.	
	227	STÜHLINGER, M., et al. (1994) "Clinical therapy and HER-2 oncogene amplification in breast cancer: Chemo-vs radiotherapy" <i>J. Steriod Biochem. Mol. Biol.</i> 49 (1):39-42.	
	228	SUGARMAN, B.J., et al. (1985) "Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro" <i>Science</i> 230 (4728):943-945.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	229	SUKI, S., et al. (1995) "Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase" <i>Leukemia and Lymphoma</i> 18:87-92.	
	230	SUKUMAR, S., et al. (1990) "Specific patterns of oncogene activation in transplacentally induced tumors" <i>PNAS USA</i> 87:718-722.	
O P E MAY 30 2001 293 PATENT & TRADEMARK OFFICE	231	TAKEISHI, K., et al. (1985) "Nucleotide sequence of a functional cDNA for human thymidylate synthase" <i>Nucl. Acid Res.</i> 13(6):2035-2043.	
	232	TANNOCK, I.F. (December 1996) "Treatment of cancer with radiation and drugs" <i>J. Clin. Oncol.</i> 14(12):3156-3174.	
	233	TEH, B.T., et al. (1999) "Tumor suppressor genes (TSG)" <i>Anticancer Research</i> 19:4715-4728.	
	234	TENNANT, B.C., et al. (1998) "Antiviral activity and toxicity of fluridine in the woodchuck model of hepatitis B virus infection" <i>Hepatol.</i> 28(1):179-191.	
	235	TOLSTIKOV, V.V., et al. (1997) "Synthesis and DNA duplex stabilities of oligonucleotides containing C-5-(3-methoxypropynyl)-2'-deoxyuridine residues" <i>Nucleosides & Nucleotides</i> 16(3):215-225.	
	236	TROUTNER, D.E. (1987) "Chemical and physical properties of radionuclides" <i>Nucl. Med. Biol.</i> 14(3):171-176.	
	237	TSavaris, N., et al. (1990) "Multimodal Biochemical Modulation of 5-Fluorouracil Activity in Advanced Colorectal Cancer with Allopurinol, Folinic Acid and Dipyridamol" <i>J. Chemother.</i> 2(2):123-126.	
	238	UBEDA, M., et al. (1997) "The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspase-3 (CPP32/YAMA) during fas-induced apoptosis" <i>J. Biol. Chem.</i> 272(31):19562-19568.	
	239	VALETTE, G., et al. (1996) "Decomposition pathways and <i>in vitro</i> HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates" <i>J. Med. Chem.</i> 39:1981-1990	
	240	VAN DE VIJVER, M., et al. (1987) "Amplification of the <i>neu</i> (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene" <i>Mol. Cell. Biol.</i> 7(5):2019-2023.	
	241	VOLM, M., et al. (1992) "Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase- π in human lung tumors" <i>Cancer</i> 70(4):764-769.	
	242	WADLER, S., et al. (September 1987) "Phase II Trial of Oral Methotrexate and Dipyridamole in Colorectal Carcinoma" <i>Cancer Treat. Rep.</i> 71(9):821-824.	
	243	WAHBA, A.J., et al. (March 1961) "Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate" <i>J. Biol. Chem.</i> 236(3):PC11-PC12.	
	244	WALLIS, M.P., et al. (1999) "Synthesis and anit-HIV activity of C4-modified pyrimidine nucleosides" <i>Il Farmaco</i> 54:83-89.	
	245	WANG, S., et al. (1996) "Identification and characterization of Ich-3, a member of the interleukin-1 β converting enzyme (ICE/Ced-3 family and an upstream regulator if ICE" <i>J. Biol. Chem.</i> 271(34):20580-20587.	
	246	WATAYA, Y., et al. (April 1979) " <i>trans</i> -5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridylate: A mechanism-based inhibitor of thymidylate synthetase" <i>J. Med. Chem.</i> 22(4):339-340.	
	247	WETTERGREN, Y., et al. (1994) "Drug-specific rearrangements of chromosome 12 in hydroxyurea-resistance mouse SEWA cells: Support for chromosomal breakage model of gene amplification" <i>Somatic Cell Mol. Genet.</i> 20(4):267-285.	
	248	WHALEN, R., et al. (1998) "Human glutathione S-transferases" <i>Seminars in Liver Disease</i> 18(4):345-358.	
	249	WILLSON, J. K.V., et al. (October 1, 1988) "Phase I Clinical Trial of a Combination of Dipyridamole and Acivicin Based Upon Inhibition of Nucleoside Salvage" <i>Cancer Res.</i> 48:5585-5590.	
	250	WRIGHT, AMP, et al. (2000) "Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemia lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibriative nucleoside transport" <i>Leukemia</i> 14:52-60.	
	251	YEN, Y., et al. (July 15, 1994) "Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine" <i>Cancer Res.</i> 54:3686-3691.	
	252	YIN, Y., et al. (1992) "Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles" <i>Cell</i> 70:937-948.	
	253	ZEID, I.F., et al. (1999) "Synthesis of new thiolated acyclonucleosides with potential anti-HBV activity" <i>Nucleosides & Nucleotides</i> 18(1):95-111.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
--------------------	-----------------------	---	----------------

	254	ZHOU, Q., et al. (1997) "Target protease specificity of the viral serpin CrmA" <i>J. of Biol. Chem.</i> 272(12):7797-7800.	
--	-----	--	--

Examiner's Signature	Date Considered
----------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

